Difficulty: Medium
Average Score: 64%
Practice
Indicate a partial mu receptor agonist, which has 20-60 times analgesic potency of morphine, and a longer duration of action:
Correct answer
B
Rationale
In the context of Advanced Pharmacology Across the Lifespan, understanding the nuances of opioid pharmacology is crucial. In this scenario, the correct answer is B) Buprenorphine. Buprenorphine is a partial mu receptor agonist with unique properties that make it suitable for managing pain and opioid use disorder.
Buprenorphine has 20-60 times the analgesic potency of morphine due to its high affinity for the mu receptor, making it effective in managing moderate to severe pain. Its partial agonist activity also confers a ceiling effect on respiratory depression, reducing the risk of overdose compared to full agonists like morphine.
Additionally, buprenorphine has a longer duration of action compared to other opioids, allowing for less frequent dosing and improved adherence to treatment regimens. This prolonged action is attributed to its high lipophilicity and slow dissociation from the mu receptor.
Now, let's analyze why the other options are incorrect:
A) Pentazocine is a mixed opioid receptor agonist/antagonist with lower analgesic potency compared to buprenorphine.
C) Nalbuphine is a kappa receptor agonist and mu receptor antagonist, lacking the same analgesic potency and duration of action as buprenorphine.
D) Naltrexone is an opioid receptor antagonist used in the treatment of opioid overdose and addiction, not for its analgesic properties.
Understanding the pharmacological differences between these opioid medications is vital for healthcare providers to make informed decisions regarding pain management and opioid use disorder treatment in diverse patient populations across the lifespan.
Buprenorphine has 20-60 times the analgesic potency of morphine due to its high affinity for the mu receptor, making it effective in managing moderate to severe pain. Its partial agonist activity also confers a ceiling effect on respiratory depression, reducing the risk of overdose compared to full agonists like morphine.
Additionally, buprenorphine has a longer duration of action compared to other opioids, allowing for less frequent dosing and improved adherence to treatment regimens. This prolonged action is attributed to its high lipophilicity and slow dissociation from the mu receptor.
Now, let's analyze why the other options are incorrect:
A) Pentazocine is a mixed opioid receptor agonist/antagonist with lower analgesic potency compared to buprenorphine.
C) Nalbuphine is a kappa receptor agonist and mu receptor antagonist, lacking the same analgesic potency and duration of action as buprenorphine.
D) Naltrexone is an opioid receptor antagonist used in the treatment of opioid overdose and addiction, not for its analgesic properties.
Understanding the pharmacological differences between these opioid medications is vital for healthcare providers to make informed decisions regarding pain management and opioid use disorder treatment in diverse patient populations across the lifespan.